CytRx Corporation (CYTR) financial statements (2021 and earlier)

Company profile

Business Address 11726 SAN VICENTE BOULEVARD
LOS ANGELES, CA 90049
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:10131515161919
Cash and cash equivalents1013151516819
Short-term investments     10 
Other undisclosed cash, cash equivalents, and short-term investments     (0) 
Receivables0100000
Assets held-for-sale, not part of disposal group      0
Other undisclosed current assets1101110
Total current assets:11151516172020
Noncurrent Assets
Operating lease, right-of-use asset1111   
Property, plant and equipment0000000
Other noncurrent assets0000000
Total noncurrent assets:1111000
TOTAL ASSETS:12151617172020
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3311221
Accounts payable1311121
Accrued liabilities1   1  
Employee-related liabilities0   0  
Debt     00
Disposal group, including discontinued operation     00
Other undisclosed current liabilities02110  
Total current liabilities:3522221
Noncurrent Liabilities
Long-term debt and lease obligation0011   
Operating lease, liability0011   
Other undisclosed noncurrent liabilities(0)(0)(1)    
Total noncurrent liabilities: 011   
Other undisclosed liabilities     11
Total liabilities:3533232
Stockholders' equity
Stockholders' equity attributable to parent9101314151718
Common stock0000000
Additional paid in capital480479479479479478478
Accumulated deficit(471)(469)(467)(465)(464)(461)(460)
Total stockholders' equity:9101314151718
Other undisclosed liabilities and equity   (1)   
TOTAL LIABILITIES AND EQUITY:12151617172020

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(1)(3)(1)(1)(3)(2)(2)
Operating loss:(1)(3)(1)(1)(3)(2)(2)
Nonoperating income0000000
Investment income, nonoperating0000000
Other nonoperating income (expense)000(0)0(0)0
Loss from continuing operations before income taxes:(1)(3)(1)(1)(3)(1)(1)
Other undisclosed income (loss) from continuing operations(0)   0  
Net loss:(1)(3)(1)(1)(3)(1)(1)
Other undisclosed net income (loss) attributable to parent    (0)00
Net loss available to common stockholders, diluted:(1)(3)(1)(1)(3)(1)(1)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(1)(3)(1)(1)(3)(1)(1)
Comprehensive loss, net of tax, attributable to parent:(1)(3)(1)(1)(3)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: